# The Novo Nordisk CEO criticizes Pharmacy Benefit Managers (PBMs) during a US Senate hearing. # There is a focus on high list prices by PBMs in the US pharmaceutical market. # The impact of PBMs on drug pricing and access to medications is questioned by the CEO. # The need for transparency and accountability within the PBM industry is emphasized. — ## H1: Novo Nordisk CEO Criticizes PBMs in US Senate Hearing During a recent US Senate hearing, the CEO of Novo Nordisk targeted Pharmacy Benefit Managers (PBMs), raising concerns about their favoritism towards high list prices. The CEO emphasized the influence PBMs have on drug pricing in the US pharmaceutical market, shedding light on the impact this has on both patients and healthcare providers. With a call for transparency and accountability within the PBM sector, the CEO sparked a discussion on the need for fair pricing and improved access to medications. Hot Take: It is essential for stakeholders in the pharmaceutical industry to work towards a system that prioritizes affordability and accessibility for all individuals seeking essential healthcare products and services. Contact Mindful Evolution today at https://yourmindfulevolution.com or call or text us at 954-639-9960 to start your weight loss journey with professional guidance and support. Weight Loss Disclaimer: Individual results may vary. Mindful Evolution offers telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia. —